- Home
- FRGE vs ALDX Comparison
FRGE vs ALDX Comparison
Compare FRGE & ALDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FRGE | ALDX |
|---|---|---|
| Founded | 2014 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 354.6M | 293.0M |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | FRGE | ALDX |
|---|---|---|
| Price | $44.42 | $4.60 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 2 |
| Target Price | ★ $38.25 | $9.50 |
| AVG Volume (30 Days) | 642.2K | ★ 928.5K |
| Earning Date | 11-13-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $92,884,000.00 | N/A |
| Revenue This Year | $33.10 | N/A |
| Revenue Next Year | $24.07 | $36.25 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 16.40 | N/A |
| 52 Week Low | $6.60 | $1.14 |
| 52 Week High | $44.76 | $7.20 |
Technical Indicators
Market Signals| Indicator | FRGE | ALDX |
|---|---|---|
| Relative Strength Index (RSI) | 86.33 | 40.00 |
| Support Level | $44.29 | $4.67 |
| Resistance Level | $44.41 | $5.04 |
| Average True Range (ATR) | 0.19 | 0.28 |
| MACD | -0.92 | -0.04 |
| Stochastic Oscillator | 93.81 | 3.14 |
Price Performance
Historical ComparisonAbout FRGE Forge Global Holdings Inc.
Forge Global Holdings Inc is a financial service platform created to serve the needs of the private market. It provides marketplace infrastructure, data services, and technology solutions for private market participants. The company offers a trusted trading platform, proprietary data and insights to inform investment strategies, along with custody services to help companies, shareholders, institutions and accredited investors confidently navigate and transact in the private market.
About ALDX Aldeyra Therapeutics Inc.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.